{"id":{"repo_id":"greece","oai_identifier":"oai:10442/0592"},"canonical_url":"https://search.dev.ndltd.org/etd/greece/oai:10442/0592","repository":{"repo_id":"greece","name":"Greek National Archive of PhD Theses","base_url":"https://phdtheses.ekt.gr/eadd_oai/request"},"display":{"title":"ΑΝΑΣΤΟΛΕΙΣ ΤΥΠΟΥ \"ΑΝΤΙΠΡΟΘΡΟΜΒΙΝΑΣΗ\". ΚΛΙΝΙΚΟΕΡΓΑΣΤΗΡΙΑΚΗ ΜΕΛΕΤΗ","abstract":"THE LUPUS ANTICOAGULANT WAS DETECTED IN THE PLASMA OF 44 ADULTS DURING A 6-YEAR-PERIOD AT THE CENTRAL LABORATORY OF HEMOSTASIS IN THE HOSPITAL HENRI MENDER (FRANCE). THE CONSIDERABLE NUMBER OF PATIENTS AND THEIR NON-SELECTIVE RECRUITEMENT HAS PERMITTED TO DRAW VALUABLE CONCLUSIONS FROM CAREFUL STATISTICAL ANALYSIS OF CLINICAL AND LABORATORY DATA. THE MEAN DURATION OF FOLLOW-UP WAS 14 MONTHS AND EACH PATIENT WAS SUBJECTED TO COAGULATION TESTS 1 TO 12 TIMES (MEAN 3,16+2,4). OUR RESULTS DEMONSTRATE CLEARLY THE HIGH INCIDENCE OF THIS INHIBITOR AMONG PATIENTS WITHOUT SLE WHO ON THE OTHER HAND, PRESENT POSITIVE ANTINUCLEAR ANTIBODIES TESTS, LOW COMPLEMENT VALUES AND HIGH ESR. THE RELATION OF THIS ANTICOAGULANT TO DRUG INTAKE, THE ASSOCIATION OR DISSOCIATION TO THROMBOPENIA, BFP-STΓ, THROMBOSIS SPONTANEOUS FETAL WASTE AND OTHER OBSTETRICAL COMPLICATIONS ARE ANALYZED AND DISCUSSED AS WELL AS THE EVOLUTION OF THE INHIBITOR IN TIME AND THE INFLUENCE OF THERAPEUTIC MEASURES. OUR RESULTS PROVE THAT THE LUPUS ANTICOAGULANT IS \"INNOCENT\" SO FAR AS BLEED MANIFESTATIONS, PROLONGATION OF THROMBIN TIME AND DECREASE IN THE LEVEL OF FACTOR II ARE CONCERNED. BESIDES USEFUL PATHOGENIC CLUES, SPECIAL ASPECTS OF THE COAGULATION PROFILE ARE ANALYZED AND DISCUSSED, SUCHAS THE \"COFACTOR\" EFFECT, THE INTERFERENCE OF THE INHIBITOR IN THE ONE-STAGE MEASUREMENT OF THE FACTORS VIII, IX, XI, XII ETC .","abstract_html":"THE LUPUS ANTICOAGULANT WAS DETECTED IN THE PLASMA OF 44 ADULTS DURING A 6-YEAR-PERIOD AT THE CENTRAL LABORATORY OF HEMOSTASIS IN THE HOSPITAL HENRI MENDER (FRANCE). THE CONSIDERABLE NUMBER OF PATIENTS AND THEIR NON-SELECTIVE RECRUITEMENT HAS PERMITTED TO DRAW VALUABLE CONCLUSIONS FROM CAREFUL STATISTICAL ANALYSIS OF CLINICAL AND LABORATORY DATA. THE MEAN DURATION OF FOLLOW-UP WAS 14 MONTHS AND EACH PATIENT WAS SUBJECTED TO COAGULATION TESTS 1 TO 12 TIMES (MEAN 3,16+2,4). OUR RESULTS DEMONSTRATE CLEARLY THE HIGH INCIDENCE OF THIS INHIBITOR AMONG PATIENTS WITHOUT SLE WHO ON THE OTHER HAND, PRESENT POSITIVE ANTINUCLEAR ANTIBODIES TESTS, LOW COMPLEMENT VALUES AND HIGH ESR. THE RELATION OF THIS ANTICOAGULANT TO DRUG INTAKE, THE ASSOCIATION OR DISSOCIATION TO THROMBOPENIA, BFP-STΓ, THROMBOSIS SPONTANEOUS FETAL WASTE AND OTHER OBSTETRICAL COMPLICATIONS ARE ANALYZED AND DISCUSSED AS WELL AS THE EVOLUTION OF THE INHIBITOR IN TIME AND THE INFLUENCE OF THERAPEUTIC MEASURES. OUR RESULTS PROVE THAT THE LUPUS ANTICOAGULANT IS "INNOCENT" SO FAR AS BLEED MANIFESTATIONS, PROLONGATION OF THROMBIN TIME AND DECREASE IN THE LEVEL OF FACTOR II ARE CONCERNED. BESIDES USEFUL PATHOGENIC CLUES, SPECIAL ASPECTS OF THE COAGULATION PROFILE ARE ANALYZED AND DISCUSSED, SUCHAS THE "COFACTOR" EFFECT, THE INTERFERENCE OF THE INHIBITOR IN THE ONE-STAGE MEASUREMENT OF THE FACTORS VIII, IX, XI, XII ETC .","abstract_has_math":false,"creators":["Χασαποπούλου-Ματάμη, Ελένη"],"institution":"University of Patras","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":1987,"date_issued":"1987","date_published":"1987","updated_at":"2026-07-24T02:25:21Z","subjects":["ΑΝΤΙΠΡΟΘΡΟΜΒΙΝΑΣΗ","Αντιπυρηνικά αντισώματα","ΕΠΙΚΤΗΤΟΙ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΠΗΞΗΣ","Επιπλοκές κύησης","Θρομβώσεις","ΨΕΥΔΗΣ ΘΕΤΙΚΕΣ ΟΡΟΑΝΤΙΔΡΑΣΕΙΣ ΓΙΑ ΣΥΦΙΛΗ","ACQUIRED COAGULATION INHIBITOR","Antinuclear antibodies","BFP-STS","DRUG-INDUCED LUPUS-LIKE SYNDROMES","OBSTETRICAL COMPLICATIONS","THE LUPUS ANTICOAGULANT","Thrombosis","Ιατρική και Επιστήμες Υγείας","Κλινική Ιατρική","Medical and Health Sciences","Clinical Medicine"],"languages":["gre"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["10.12681/eadd/0592"],"render_values":[{"text":"10.12681/eadd/0592","href":"https://doi.org/10.12681/eadd/0592","code":true}]}]},"links":{"outbound_url":"http://hdl.handle.net/10442/hedi/0592","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Χασαποπούλου-Ματάμη, Ελένη"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["1987"]},{"key":"dc:publisher","label":"Institution","values":["University of Patras","Πανεπιστήμιο Πατρών"]},{"key":"dc:type","label":"Dc Type","values":["PhD Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["ΑΝΤΙΠΡΟΘΡΟΜΒΙΝΑΣΗ","Αντιπυρηνικά αντισώματα","ΕΠΙΚΤΗΤΟΙ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΠΗΞΗΣ","Επιπλοκές κύησης","Θρομβώσεις","ΨΕΥΔΗΣ ΘΕΤΙΚΕΣ ΟΡΟΑΝΤΙΔΡΑΣΕΙΣ ΓΙΑ ΣΥΦΙΛΗ","ACQUIRED COAGULATION INHIBITOR","Antinuclear antibodies","BFP-STS","DRUG-INDUCED LUPUS-LIKE SYNDROMES","OBSTETRICAL COMPLICATIONS","THE LUPUS ANTICOAGULANT","Thrombosis","Ιατρική και Επιστήμες Υγείας","Κλινική Ιατρική","Medical and Health Sciences","Clinical Medicine"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["gre"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["10.12681/eadd/0592","http://hdl.handle.net/10442/hedi/0592"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["THE LUPUS ANTICOAGULANT WAS DETECTED IN THE PLASMA OF 44 ADULTS DURING A 6-YEAR-PERIOD AT THE CENTRAL LABORATORY OF HEMOSTASIS IN THE HOSPITAL HENRI MENDER (FRANCE). THE CONSIDERABLE NUMBER OF PATIENTS AND THEIR NON-SELECTIVE RECRUITEMENT HAS PERMITTED TO DRAW VALUABLE CONCLUSIONS FROM CAREFUL STATISTICAL ANALYSIS OF CLINICAL AND LABORATORY DATA. THE MEAN DURATION OF FOLLOW-UP WAS 14 MONTHS AND EACH PATIENT WAS SUBJECTED TO COAGULATION TESTS 1 TO 12 TIMES (MEAN 3,16+2,4). OUR RESULTS DEMONSTRATE CLEARLY THE HIGH INCIDENCE OF THIS INHIBITOR AMONG PATIENTS WITHOUT SLE WHO ON THE OTHER HAND, PRESENT POSITIVE ANTINUCLEAR ANTIBODIES TESTS, LOW COMPLEMENT VALUES AND HIGH ESR. THE RELATION OF THIS ANTICOAGULANT TO DRUG INTAKE, THE ASSOCIATION OR DISSOCIATION TO THROMBOPENIA, BFP-STΓ, THROMBOSIS SPONTANEOUS FETAL WASTE AND OTHER OBSTETRICAL COMPLICATIONS ARE ANALYZED AND DISCUSSED AS WELL AS THE EVOLUTION OF THE INHIBITOR IN TIME AND THE INFLUENCE OF THERAPEUTIC MEASURES. OUR RESULTS PROVE THAT THE LUPUS ANTICOAGULANT IS \"INNOCENT\" SO FAR AS BLEED MANIFESTATIONS, PROLONGATION OF THROMBIN TIME AND DECREASE IN THE LEVEL OF FACTOR II ARE CONCERNED. BESIDES USEFUL PATHOGENIC CLUES, SPECIAL ASPECTS OF THE COAGULATION PROFILE ARE ANALYZED AND DISCUSSED, SUCHAS THE \"COFACTOR\" EFFECT, THE INTERFERENCE OF THE INHIBITOR IN THE ONE-STAGE MEASUREMENT OF THE FACTORS VIII, IX, XI, XII ETC .","ΑΝΤΙΠΡΟΘΡΟΜΒΙΝΑΣΗ ΑΝΕΥΡΕΘΗΚΕ ΣΤΟ ΠΛΑΣΜΑ 44 ΕΝΗΛΙΚΩΝ ΚΑΤΑ ΤΗΝ ΔΙΑΡΚΕΙΑ ΜΙΑΣ ΕΞΑΕΤΙΑΣ, ΣΤΟ ΕΡΓΑΣΤΗΡΙΟ ΑΙΜΟΣΤΑΣΗΣ ΤΟΥ ΝΟΣΟΚΟΜΕΙΟΥ HENRI NENDER (ΓΑΛΛΙΑ). Η ΔΙΑΡΚΕΙΑ ΠΑΡΑΚΟΛΟΥΘΗΣΗΣ ΤΩΝ ΑΣΘΕΝΩΝ ΗΤΑΝ ΚΑΤΑ ΜΕΣΟ ΟΡΟ 14 ΜΗΝΕΣ, ΚΑΙ ΑΣΘΕΝΕΙΣ ΥΠΕΣΤΗ ΕΛΕΓΧΟ ΤΩΝ ΔΟΚΙΜΑΣΙΩΝ ΠΗΞΗΣ, 1 ΕΩΣ 12 ΦΟΡΕΣ (ΜΕΣΟΣ ΟΡΟΣ 3,16+2,4). ΧΑΡΙΣ ΣΤΟΝ ΣΗΜΑΝΙΚΟ ΑΡΙΘΜΟ ΤΩΝ ΑΣΘΕΝΩΝ ΚΑΙ ΤΗΝ ΜΗ ΕΚΛΕΚΤΙΚΗ ΕΠΙΛΟΓΗ ΤΟΥΣ, ΠΡΟΣΕΚΤΙΚΗ ΑΝΑΛΥΣΗ ΤΩΝ ΚΛΙΝΙΚΩΝ ΚΑΙ ΕΡΓΑΣΤΗΡΙΑΚΩΝ ΔΕΔΟΜΕΝΩΝ ΟΔΗΓΗΣΕ ΣΕ ΑΞΙΟΛΟΓΑ ΣΥΜΠΕΡΑΣΜΑΤΑ. ΤΑΑΠΟΤΕΛΕΣΜΑΤΑ ΜΑΣ ΑΠΟΔΕΙΚΝΥΟΥΝ ΣΑΦΩΣ ΤΗΝ ΜΕΓΑΛΗ ΣΥΧΝΟΤΗΤΑ ΜΕ ΤΗΝ ΟΠΟΙΑ ΑΝΕΥΡΙΣΚΟΝΤΑΙ ΑΣΘΕΝΕΙΣ ΧΩΡΙΣ ΣΕΛ ΟΙ ΟΠΟΙΟΙ ΕΞ'ΑΛΛΟΥ ΕΜΦΑΝΙΖΟΥΝ ΣΕ ΜΕΓΑΛΟ ΠΟΣΟΣΤΟ ΘΕΤΙΚΑΑΝΤΙΠΥΡΗΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ, ΧΑΜΗΛΕΣ ΤΙΜΕΣ ΣΥΜΠΛΗΡΩΜΑΤΟΣ ΚΑΙ ΥΨΗΛΗ ΤΑΧΥΤΗΤΑ ΚΑΘΙΖΗΣΗΣ ΕΡΥΘΡΩΝ ΑΙΜΟΣΦΑΙΡΙΩΝ. ΑΝΑΛΥΟΝΤΑΙ ΚΑΙ ΣΥΖΗΤΟΥΝΤΑΙ ΟΙ ΠΙΘΑΝΟΤΗΤΕΣ ΙΑΤΡΟΓΕΝΟΥΣΕΜΦΑΝΙΣΗΣ ΤΟΥ ΑΝΑΣΤΟΛΕΑ, Η ΣΧΕΣΗ ΤΟΥ 'Η ΔΙΑΦΟΡΟΠΟΙΗΣΗ ΤΟΥ ΩΣ ΠΡΟΣ ΤΗΝ ΘΡΟΜΒΙΝΗ, ΨΕΥΔΩΝ ΘΕΤΙΚΕΣ ΟΡΟΑΝΤΙΔΡΑΣΕΙΣ ΓΙΑ ΣΥΦΙΛΗ, ΘΡΟΜΒΩΣΗ, ΑΥΤΟΜΑΤΕΣ ΑΠΟΒΟΛΕΣ ΚΑΙ ΑΛΛΕΣ ΜΑΙΕΥΤΙΚΕΣ ΕΠΙΠΛΟΚΕΣ. ΤΑ ΑΠΟΤΕΛΕΣΜΑΤΑ ΜΑΣ ΑΠΟΔΕΙΚΝΥΟΥΝ ΟΤΙ ΔΕΝ ΕΥΘΥΝΕΤΑΙ Η ΑΝΤΙΠΡΟΘΡΟΜΒΙΝΑΣΗ ΓΙΑ ΑΙΜΟΡΡΑΓΙΚΕΣ ΕΚΔΗΛΩΣΕΙΣ, ΠΑΡΑΤΑΣΗ ΤΟΥ ΧΡΟΝΟΥ ΘΡΟΜΒΙΝΗΣ ΚΑΙ ΜΕΙΩΣΗ ΤΟΥ ΕΠΙΠΕΔΟΥ ΠΡΟΘΡΟΜΒΙΝΗΣ ΣΤΟ ΠΛΑΣΜΑ. ΣΥΖΗΤΟΥΝΤΑΙ ΠΑΘΟΓΕΝΕΤΙΚΕΣ ΧΩΡΙΣ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΚΑΙ ΑΝΑΛΥΟΝΤΑΙ ΕΝΔΙΑΦΕΡΟΥΣΕΣ ΠΛΕΥΡΕΣ ΤΟΥ ΤΕΧΝΙΚΟΥ ΜΕΡΟΥΣ ΤΩΝ ΔΟΚΙΜΑΣΙΩΝ ΤΗΣ ΠΗΞΗΣ ΟΠΩΣ ΚΑΙ ΤΟ ΦΑΙΝΟΜΕΝΟ \"ΣΥΝΕΡΓΟΥ\" ΠΑΡΑΓΟΝΤΑΣ ΚΑΙ ΤΟ ΦΑΙΝΟΜΕΝΟ \"ΠΑΡΕΝΟΧΛΗΣΗΣ\" ΤΗΣ ΜΕΤΡΗΣΗΣ ΤΩΝ ΠΑΡΑΓΟΝΤΩΝ VII, IX, XI, XII."]},{"key":"dc:title","label":"Title","values":["ΑΝΑΣΤΟΛΕΙΣ ΤΥΠΟΥ \"ΑΝΤΙΠΡΟΘΡΟΜΒΙΝΑΣΗ\". ΚΛΙΝΙΚΟΕΡΓΑΣΤΗΡΙΑΚΗ ΜΕΛΕΤΗ","THE LUPUS ANTICOAGULANT: A STUDY OF CLINICAL AND LABORATORY ASSOCIATIONS"]}]}],"canonical_facts":{"dc:creator":["Χασαποπούλου-Ματάμη, Ελένη"],"dc:date":["1987"],"dc:description":["THE LUPUS ANTICOAGULANT WAS DETECTED IN THE PLASMA OF 44 ADULTS DURING A 6-YEAR-PERIOD AT THE CENTRAL LABORATORY OF HEMOSTASIS IN THE HOSPITAL HENRI MENDER (FRANCE). THE CONSIDERABLE NUMBER OF PATIENTS AND THEIR NON-SELECTIVE RECRUITEMENT HAS PERMITTED TO DRAW VALUABLE CONCLUSIONS FROM CAREFUL STATISTICAL ANALYSIS OF CLINICAL AND LABORATORY DATA. THE MEAN DURATION OF FOLLOW-UP WAS 14 MONTHS AND EACH PATIENT WAS SUBJECTED TO COAGULATION TESTS 1 TO 12 TIMES (MEAN 3,16+2,4). OUR RESULTS DEMONSTRATE CLEARLY THE HIGH INCIDENCE OF THIS INHIBITOR AMONG PATIENTS WITHOUT SLE WHO ON THE OTHER HAND, PRESENT POSITIVE ANTINUCLEAR ANTIBODIES TESTS, LOW COMPLEMENT VALUES AND HIGH ESR. THE RELATION OF THIS ANTICOAGULANT TO DRUG INTAKE, THE ASSOCIATION OR DISSOCIATION TO THROMBOPENIA, BFP-STΓ, THROMBOSIS SPONTANEOUS FETAL WASTE AND OTHER OBSTETRICAL COMPLICATIONS ARE ANALYZED AND DISCUSSED AS WELL AS THE EVOLUTION OF THE INHIBITOR IN TIME AND THE INFLUENCE OF THERAPEUTIC MEASURES. OUR RESULTS PROVE THAT THE LUPUS ANTICOAGULANT IS \"INNOCENT\" SO FAR AS BLEED MANIFESTATIONS, PROLONGATION OF THROMBIN TIME AND DECREASE IN THE LEVEL OF FACTOR II ARE CONCERNED. BESIDES USEFUL PATHOGENIC CLUES, SPECIAL ASPECTS OF THE COAGULATION PROFILE ARE ANALYZED AND DISCUSSED, SUCHAS THE \"COFACTOR\" EFFECT, THE INTERFERENCE OF THE INHIBITOR IN THE ONE-STAGE MEASUREMENT OF THE FACTORS VIII, IX, XI, XII ETC .","ΑΝΤΙΠΡΟΘΡΟΜΒΙΝΑΣΗ ΑΝΕΥΡΕΘΗΚΕ ΣΤΟ ΠΛΑΣΜΑ 44 ΕΝΗΛΙΚΩΝ ΚΑΤΑ ΤΗΝ ΔΙΑΡΚΕΙΑ ΜΙΑΣ ΕΞΑΕΤΙΑΣ, ΣΤΟ ΕΡΓΑΣΤΗΡΙΟ ΑΙΜΟΣΤΑΣΗΣ ΤΟΥ ΝΟΣΟΚΟΜΕΙΟΥ HENRI NENDER (ΓΑΛΛΙΑ). Η ΔΙΑΡΚΕΙΑ ΠΑΡΑΚΟΛΟΥΘΗΣΗΣ ΤΩΝ ΑΣΘΕΝΩΝ ΗΤΑΝ ΚΑΤΑ ΜΕΣΟ ΟΡΟ 14 ΜΗΝΕΣ, ΚΑΙ ΑΣΘΕΝΕΙΣ ΥΠΕΣΤΗ ΕΛΕΓΧΟ ΤΩΝ ΔΟΚΙΜΑΣΙΩΝ ΠΗΞΗΣ, 1 ΕΩΣ 12 ΦΟΡΕΣ (ΜΕΣΟΣ ΟΡΟΣ 3,16+2,4). ΧΑΡΙΣ ΣΤΟΝ ΣΗΜΑΝΙΚΟ ΑΡΙΘΜΟ ΤΩΝ ΑΣΘΕΝΩΝ ΚΑΙ ΤΗΝ ΜΗ ΕΚΛΕΚΤΙΚΗ ΕΠΙΛΟΓΗ ΤΟΥΣ, ΠΡΟΣΕΚΤΙΚΗ ΑΝΑΛΥΣΗ ΤΩΝ ΚΛΙΝΙΚΩΝ ΚΑΙ ΕΡΓΑΣΤΗΡΙΑΚΩΝ ΔΕΔΟΜΕΝΩΝ ΟΔΗΓΗΣΕ ΣΕ ΑΞΙΟΛΟΓΑ ΣΥΜΠΕΡΑΣΜΑΤΑ. ΤΑΑΠΟΤΕΛΕΣΜΑΤΑ ΜΑΣ ΑΠΟΔΕΙΚΝΥΟΥΝ ΣΑΦΩΣ ΤΗΝ ΜΕΓΑΛΗ ΣΥΧΝΟΤΗΤΑ ΜΕ ΤΗΝ ΟΠΟΙΑ ΑΝΕΥΡΙΣΚΟΝΤΑΙ ΑΣΘΕΝΕΙΣ ΧΩΡΙΣ ΣΕΛ ΟΙ ΟΠΟΙΟΙ ΕΞ'ΑΛΛΟΥ ΕΜΦΑΝΙΖΟΥΝ ΣΕ ΜΕΓΑΛΟ ΠΟΣΟΣΤΟ ΘΕΤΙΚΑΑΝΤΙΠΥΡΗΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ, ΧΑΜΗΛΕΣ ΤΙΜΕΣ ΣΥΜΠΛΗΡΩΜΑΤΟΣ ΚΑΙ ΥΨΗΛΗ ΤΑΧΥΤΗΤΑ ΚΑΘΙΖΗΣΗΣ ΕΡΥΘΡΩΝ ΑΙΜΟΣΦΑΙΡΙΩΝ. ΑΝΑΛΥΟΝΤΑΙ ΚΑΙ ΣΥΖΗΤΟΥΝΤΑΙ ΟΙ ΠΙΘΑΝΟΤΗΤΕΣ ΙΑΤΡΟΓΕΝΟΥΣΕΜΦΑΝΙΣΗΣ ΤΟΥ ΑΝΑΣΤΟΛΕΑ, Η ΣΧΕΣΗ ΤΟΥ 'Η ΔΙΑΦΟΡΟΠΟΙΗΣΗ ΤΟΥ ΩΣ ΠΡΟΣ ΤΗΝ ΘΡΟΜΒΙΝΗ, ΨΕΥΔΩΝ ΘΕΤΙΚΕΣ ΟΡΟΑΝΤΙΔΡΑΣΕΙΣ ΓΙΑ ΣΥΦΙΛΗ, ΘΡΟΜΒΩΣΗ, ΑΥΤΟΜΑΤΕΣ ΑΠΟΒΟΛΕΣ ΚΑΙ ΑΛΛΕΣ ΜΑΙΕΥΤΙΚΕΣ ΕΠΙΠΛΟΚΕΣ. ΤΑ ΑΠΟΤΕΛΕΣΜΑΤΑ ΜΑΣ ΑΠΟΔΕΙΚΝΥΟΥΝ ΟΤΙ ΔΕΝ ΕΥΘΥΝΕΤΑΙ Η ΑΝΤΙΠΡΟΘΡΟΜΒΙΝΑΣΗ ΓΙΑ ΑΙΜΟΡΡΑΓΙΚΕΣ ΕΚΔΗΛΩΣΕΙΣ, ΠΑΡΑΤΑΣΗ ΤΟΥ ΧΡΟΝΟΥ ΘΡΟΜΒΙΝΗΣ ΚΑΙ ΜΕΙΩΣΗ ΤΟΥ ΕΠΙΠΕΔΟΥ ΠΡΟΘΡΟΜΒΙΝΗΣ ΣΤΟ ΠΛΑΣΜΑ. ΣΥΖΗΤΟΥΝΤΑΙ ΠΑΘΟΓΕΝΕΤΙΚΕΣ ΧΩΡΙΣ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΚΑΙ ΑΝΑΛΥΟΝΤΑΙ ΕΝΔΙΑΦΕΡΟΥΣΕΣ ΠΛΕΥΡΕΣ ΤΟΥ ΤΕΧΝΙΚΟΥ ΜΕΡΟΥΣ ΤΩΝ ΔΟΚΙΜΑΣΙΩΝ ΤΗΣ ΠΗΞΗΣ ΟΠΩΣ ΚΑΙ ΤΟ ΦΑΙΝΟΜΕΝΟ \"ΣΥΝΕΡΓΟΥ\" ΠΑΡΑΓΟΝΤΑΣ ΚΑΙ ΤΟ ΦΑΙΝΟΜΕΝΟ \"ΠΑΡΕΝΟΧΛΗΣΗΣ\" ΤΗΣ ΜΕΤΡΗΣΗΣ ΤΩΝ ΠΑΡΑΓΟΝΤΩΝ VII, IX, XI, XII."],"dc:identifier":["10.12681/eadd/0592","http://hdl.handle.net/10442/hedi/0592"],"dc:language":["gre"],"dc:publisher":["University of Patras","Πανεπιστήμιο Πατρών"],"dc:subject":["ΑΝΤΙΠΡΟΘΡΟΜΒΙΝΑΣΗ","Αντιπυρηνικά αντισώματα","ΕΠΙΚΤΗΤΟΙ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΠΗΞΗΣ","Επιπλοκές κύησης","Θρομβώσεις","ΨΕΥΔΗΣ ΘΕΤΙΚΕΣ ΟΡΟΑΝΤΙΔΡΑΣΕΙΣ ΓΙΑ ΣΥΦΙΛΗ","ACQUIRED COAGULATION INHIBITOR","Antinuclear antibodies","BFP-STS","DRUG-INDUCED LUPUS-LIKE SYNDROMES","OBSTETRICAL COMPLICATIONS","THE LUPUS ANTICOAGULANT","Thrombosis","Ιατρική και Επιστήμες Υγείας","Κλινική Ιατρική","Medical and Health Sciences","Clinical Medicine"],"dc:title":["ΑΝΑΣΤΟΛΕΙΣ ΤΥΠΟΥ \"ΑΝΤΙΠΡΟΘΡΟΜΒΙΝΑΣΗ\". ΚΛΙΝΙΚΟΕΡΓΑΣΤΗΡΙΑΚΗ ΜΕΛΕΤΗ","THE LUPUS ANTICOAGULANT: A STUDY OF CLINICAL AND LABORATORY ASSOCIATIONS"],"dc:type":["PhD Thesis"]},"updated_at":"2026-07-24T02:25:21Z"}